272 related articles for article (PubMed ID: 9062581)
1. Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis.
Miura N; Horikawa I; Nishimoto A; Ohmura H; Ito H; Hirohashi S; Shay JW; Oshimura M
Cancer Genet Cytogenet; 1997 Jan; 93(1):56-62. PubMed ID: 9062581
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of telomerase activity in precancerous lesion of the liver (adenomatous hyperplasia)].
Nishimoto A; Miura N; Oshimura M
Nihon Rinsho; 1998 May; 56(5):1244-7. PubMed ID: 9613131
[TBL] [Abstract][Full Text] [Related]
3. Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status.
Saini N; Srinivasan R; Chawla Y; Sharma S; Chakraborti A; Rajwanshi A
Liver Int; 2009 Sep; 29(8):1162-70. PubMed ID: 19627485
[TBL] [Abstract][Full Text] [Related]
4. Telomere biology and telomerase mutations in cirrhotic patients with hepatocellular carcinoma.
Donaires FS; Scatena NF; Alves-Paiva RM; Podlevsky JD; Logeswaran D; Santana BA; Teixeira AC; Chen JJ; Calado RT; Martinelli ALC
PLoS One; 2017; 12(8):e0183287. PubMed ID: 28813500
[TBL] [Abstract][Full Text] [Related]
5. Telomere shortening and telomerase reactivation in dysplastic nodules of human hepatocarcinogenesis.
Oh BK; Jo Chae K; Park C; Kim K; Jung Lee W; Han KH; Nyun Park Y
J Hepatol; 2003 Nov; 39(5):786-92. PubMed ID: 14568262
[TBL] [Abstract][Full Text] [Related]
6. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
Ningarhari M; Caruso S; Hirsch TZ; Bayard Q; Franconi A; Védie AL; Noblet B; Blanc JF; Amaddeo G; Ganne N; Ziol M; Paradis V; Guettier C; Calderaro J; Morcrette G; Kim Y; MacLeod AR; Nault JC; Rebouissou S; Zucman-Rossi J
J Hepatol; 2021 May; 74(5):1155-1166. PubMed ID: 33338512
[TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of PinX1 in human hepatocellular carcinoma.
Oh BK; Chae KJ; Park C; Park YN
Oncol Rep; 2004 Oct; 12(4):861-6. PubMed ID: 15375513
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress may enhance the malignant potential of human hepatocellular carcinoma by telomerase activation.
Nishikawa T; Nakajima T; Katagishi T; Okada Y; Jo M; Kagawa K; Okanoue T; Itoh Y; Yoshikawa T
Liver Int; 2009 Jul; 29(6):846-56. PubMed ID: 19141026
[TBL] [Abstract][Full Text] [Related]
9. Telomeric 3' overhangs in chronic HBV-related hepatitis and hepatocellular carcinoma.
Lee JE; Oh BK; Choi J; Park YN
Int J Cancer; 2008 Jul; 123(2):264-272. PubMed ID: 18449889
[TBL] [Abstract][Full Text] [Related]
10. Telomere length variation and maintenance in hepatocarcinogenesis.
Yokota T; Suda T; Igarashi M; Kuroiwa T; Waguri N; Kawai H; Mita Y; Aoyagi Y
Cancer; 2003 Jul; 98(1):110-8. PubMed ID: 12833463
[TBL] [Abstract][Full Text] [Related]
11. Telomere and telomerase in chronic liver disease and hepatocarcinoma.
Carulli L; Anzivino C
World J Gastroenterol; 2014 May; 20(20):6287-92. PubMed ID: 24876749
[TBL] [Abstract][Full Text] [Related]
12. Telomeres and telomerase: new targets for the treatment of liver cirrhosis and hepatocellular carcinoma.
Lechel A; Manns MP; Rudolph KL
J Hepatol; 2004 Sep; 41(3):491-7. PubMed ID: 15336455
[No Abstract] [Full Text] [Related]
13. Telomerase is strongly activated in hepatocellular carcinoma but not in chronic hepatitis and cirrhosis.
Park YM; Choi JY; Byun BH; Cho CH; Kim HS; Kim BS
Exp Mol Med; 1998 Mar; 30(1):35-40. PubMed ID: 9873820
[TBL] [Abstract][Full Text] [Related]
14. Telomerase activity and telomere length in hepatocellular carcinoma and chronic liver disease.
Kojima H; Yokosuka O; Imazeki F; Saisho H; Omata M
Gastroenterology; 1997 Feb; 112(2):493-500. PubMed ID: 9024303
[TBL] [Abstract][Full Text] [Related]
15. Shortened telomere length in hepatocellular carcinomas and corresponding background liver tissues of patients infected with hepatitis virus.
Ohashi K; Tsutsumi M; Kobitsu K; Fukuda T; Tsujiuchi T; Okajima E; Ko S; Nakajima Y; Nakano H; Konishi Y
Jpn J Cancer Res; 1996 May; 87(5):419-22. PubMed ID: 8641975
[TBL] [Abstract][Full Text] [Related]
16. High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis.
Oh BK; Kim H; Park YN; Yoo JE; Choi J; Kim KS; Lee JJ; Park C
Lab Invest; 2008 Feb; 88(2):144-52. PubMed ID: 18158557
[TBL] [Abstract][Full Text] [Related]
17. Telomere length in human liver diseases.
Urabe Y; Nouso K; Higashi T; Nakatsukasa H; Hino N; Ashida K; Kinugasa N; Yoshida K; Uematsu S; Tsuji T
Liver; 1996 Oct; 16(5):293-7. PubMed ID: 8938628
[TBL] [Abstract][Full Text] [Related]
18. Cause-specific telomere factors deregulation in hepatocellular carcinoma.
El Idrissi M; Hervieu V; Merle P; Mortreux F; Wattel E
J Exp Clin Cancer Res; 2013 Sep; 32(1):64. PubMed ID: 24020493
[TBL] [Abstract][Full Text] [Related]
19. Telomerase activity in hepatocellular carcinoma as a predictor of postoperative recurrence.
Ohta K; Kanamaru T; Morita Y; Hayashi Y; Ito H; Yamamoto M
J Gastroenterol; 1997 Dec; 32(6):791-6. PubMed ID: 9430018
[TBL] [Abstract][Full Text] [Related]
20. [Telomere length and telomerase activity in hepatocellular carcinoma].
Nakashio R; Kitamoto M; Nakanishi T; Takaishi H; Takahashi S; Kajiyama G
Nihon Rinsho; 1998 May; 56(5):1239-43. PubMed ID: 9613130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
